BiotechTube
Eascra Biotech

Eascra Biotech

Boston, United States· Est.
eascrabiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Eascra Biotech is a private, preclinical-stage biotech founded in 2020 and based in Boston. The company has developed a proprietary, non-lipid nanoparticle platform (JBNps) inspired by DNA structures, enabling room-temperature stable delivery of therapeutics into dense tissues like cartilage and solid tumors. Its pipeline includes a therapeutic delivery platform (JBNp) and an orthopedic scaffold (JBNm), with initial focus on osteoarthritis and oncology. Eascra operates as a platform/therapeutics company and is currently pre-revenue, leveraging partnerships for development.

Orthopedics (Osteoarthritis, Cartilage Repair)Oncology

Technology Platform

Janus base nanoparticles (JBNps): DNA-inspired synthetic, non-lipid nanoparticles for room-temperature stable delivery of diverse cargoes (mRNA, siRNA, Cas9, proteins, peptides) into dense, hard-to-penetrate tissues.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The platform addresses major unmet needs in delivering biologics to dense tissues in large markets like osteoarthritis and oncology.
Room-temperature stability could provide a significant logistical and cost advantage over lipid nanoparticles for mRNA/gene therapy delivery.
Versatility across cargo types allows for multiple partnership and pipeline opportunities.

Risk Factors

High technical risk in translating novel nanoparticle platform from preclinical models to human safety and efficacy.
Faces competition from established and next-gen lipid and polymer delivery systems.
As a pre-revenue private company, faces significant financial risk and dependency on future fundraising to advance programs.

Competitive Landscape

Eascra competes with established lipid nanoparticle (LNP) companies (e.g., Acuitas, Genevant) and polymer nanoparticle developers in the broad drug delivery space. In orthopedics, it competes with cell therapy and scaffold companies for cartilage repair. Its key differentiators are the non-lipid, DNA-inspired design and claimed ability to penetrate specific dense tissues.

More companies in Drug Delivery & Formulation →More companies in United States →